Stentys First Half 2014 Revenues Rise 18%

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Regulatory News:

STENTYS (Paris:STNT) (FR0010949404 — STNT), a medical technology company commercializing in Europe the world's first and only Self-Apposing® stent to treat acute myocardial infarction (AMI), today announces revenues for the second quarter and first half of 2014, as well as cash position at June 30, 2014.

Help employers find you! Check out all the jobs and post your resume.
MORE ON THIS TOPIC